The short answer
Fenugreek seed extract has glucose effects and an uncertain low-glucose symptom report, but its added risk with tirzepatide is unknown. Review monitoring rather than relying on a spacing rule.
What this answer covers
Oral Trigonella foenum-graecum products with subcutaneous tirzepatide. The inspected trial used a specified hydroalcoholic seed extract, not food seasoning, whole seeds or every extract.
- Supplement or preparation
- Trigonella foenum-graecum
- Medication ingredient
- tirzepatide
What the seed-extract trial found
A 12-week prediabetes study found improved fasting and post-meal glucose with a particular fenugreek seed extract, without a significant HbA1c change. It excluded people taking glucose-lowering or anti-obesity medicines, so it does not establish the effect of adding the extract to tirzepatide.
The symptom report needs careful interpretation
The full study report describes one participant withdrawing after light-headedness, called possible hypoglycemia. It does not document glucose confirmation in that narrative. The signal should not be ignored, but it cannot supply a measured risk for the tirzepatide combination.
Discuss your current glucose treatment
Tirzepatide can cause low blood sugar, with greater risk when insulin or a sulfonylurea is also used. Tell the prescriber about the exact seed extract and ask whether your glucose-checking plan should change. Food seasoning and concentrated supplements are not interchangeable exposures.
A few hours apart is not an established solution
No study identified a protective spacing interval or a universal need to avoid fenugreek with tirzepatide. Stomach-emptying effects and possible glucose effects are different issues. Follow your existing plan for low readings and symptoms, and seek a medication review instead of adjusting prescribed doses yourself.
Evidence and practical considerations
Side effects & toxicity
Fenugreek seed extract can affect glucose, but the added hypoglycemia risk with tirzepatide has not been established.
- Exact scope
- Oral Trigonella foenum-graecum products with subcutaneous tirzepatide. The inspected trial used a specified hydroalcoholic seed extract, not food seasoning, whole seeds or every extract. with Exact tirzepatide RxCUI 2601723 IN, confirmed by current NLM properties. Current approved Mounjaro and Zepbound are subcutaneous injections. Indications, ages, doses and background therapies differ; oral agents and compounded admixtures are not assumed equivalent.
- Medication form and route
- Subcutaneous tirzepatide; Oral supplement
What remains uncertain
- The trial excluded glucose-lowering and anti-obesity medicines. One light-headedness withdrawal was described as possible hypoglycemia without confirmation in the narrative; no exact-pair risk estimate.
Factors that may matter: Exact preparation; Dose and duration; Diabetes and other glucose-lowering medicines; Oral intake and GI symptoms.
Read the supporting source summaries
Source 1: Current U.S. prescribing information
pi.lilly.com · Source check Sep 10, 2026
Population: Type 2 diabetes in adults and children age 10 years or older; cardiovascular risk reduction in high-risk adults with type 2 diabetes.
Glucose-dependent insulin secretion; increased hypoglycemia risk with insulin or insulin secretagogues. GI adverse reactions can cause dehydration and kidney injury. Oral drug absorption may be affected; initial acetaminophen peak fell and was delayed without a change in total exposure.
How this applies: Exact current medication guidance. Exact tirzepatide RxCUI 2601723 IN, confirmed by current NLM properties. Current approved Mounjaro and Zepbound are subcutaneous injections. Indications, ages, doses and background therapies differ; oral agents and compounded admixtures are not assumed equivalent.
Does not establish exact herb interactions or universal supplement malabsorption, spacing or replacement. Specific oral-contraceptive findings are not transferable to every oral product.
Source 2: Current U.S. prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults with obesity or overweight and comorbidity for weight management; adults with obesity and moderate to severe obstructive sleep apnea.
Warns about GI effects, volume depletion and hypoglycemia. In the type 2 diabetes weight-management trial, glucose below 54 mg/dL was more frequent with tirzepatide; concomitant sulfonylureas increased risk further. Events can also occur without diabetes.
How this applies: Retains the weight-management indication and population alongside Mounjaro guidance.
Does not imply hypoglycemia occurs only with insulin or sulfonylureas. No exact botanical subgroup or general supplement interaction rate. Obesity-trial results cannot be assigned to every diabetes or pediatric regimen.
Source 3: Original clinical research
ebi.ac.uk · Source check Sep 10, 2026
Population: 54 adults randomized in a 12-week exploratory prediabetes trial; glucose-lowering and anti-obesity medicines were excluded.
Fasting and postprandial glucose improved relative to placebo, without a significant HbA1c change. The full body reports one light-headedness withdrawal described as possible hypoglycemia.
How this applies: Retains both glucose activity and the uncertain symptom report without inventing a combination risk estimate.
Possible event was not documented as glucose-confirmed hypoglycemia in the inspected narrative; no exact tirzepatide co-use. Small exploratory manufacturer-sponsored trial. Seed extract is not equivalent to food seasoning or every preparation.
Source 4: Authoritative medication terminology
rxnav.nlm.nih.gov · Source check Sep 10, 2026
Population: Medication terminology.
Identifies tirzepatide as IN.
How this applies: Exact medication identifier.
Not clinical interaction evidence or proof of formulation equivalence.
Research assessment: · Open full citations ↗
Timing & monitoring
Evidence does not establish a universal avoid-or-separate rule for fenugreek with tirzepatide.
- Exact scope
- Oral Trigonella foenum-graecum products with subcutaneous tirzepatide. The inspected trial used a specified hydroalcoholic seed extract, not food seasoning, whole seeds or every extract. with Exact tirzepatide RxCUI 2601723 IN, confirmed by current NLM properties. Current approved Mounjaro and Zepbound are subcutaneous injections. Indications, ages, doses and background therapies differ; oral agents and compounded admixtures are not assumed equivalent.
- Medication form and route
- Subcutaneous tirzepatide; Oral supplement
What remains uncertain
- No exact timing trial. Gastric-emptying results do not establish a spacing interval that prevents systemic glucose effects.
Factors that may matter: Exact preparation; Dose and duration; Diabetes and other glucose-lowering medicines; Oral intake and GI symptoms.
Read the supporting source summaries
Source 1: Current U.S. prescribing information
pi.lilly.com · Source check Sep 10, 2026
Population: Type 2 diabetes in adults and children age 10 years or older; cardiovascular risk reduction in high-risk adults with type 2 diabetes.
Glucose-dependent insulin secretion; increased hypoglycemia risk with insulin or insulin secretagogues. GI adverse reactions can cause dehydration and kidney injury. Oral drug absorption may be affected; initial acetaminophen peak fell and was delayed without a change in total exposure.
How this applies: Exact current medication guidance. Exact tirzepatide RxCUI 2601723 IN, confirmed by current NLM properties. Current approved Mounjaro and Zepbound are subcutaneous injections. Indications, ages, doses and background therapies differ; oral agents and compounded admixtures are not assumed equivalent.
Does not establish exact herb interactions or universal supplement malabsorption, spacing or replacement. Specific oral-contraceptive findings are not transferable to every oral product.
Source 2: Original clinical research
ebi.ac.uk · Source check Sep 10, 2026
Population: Exploratory phase 1 study in healthy men and adults with type 2 diabetes.
Initial acetaminophen peak concentration fell and occurred later, while total exposure was not affected. Delay diminished with repeated treatment; some residual delay remained with rapid dose escalation in diabetes.
How this applies: Exact drug evidence distinguishes absorption rate from extent and does not address oral herbs changing subcutaneous tirzepatide absorption.
Short study, surrogate marker and no supplement pharmacokinetic testing. Does not establish reduced supplement absorption or a protective hours-apart schedule.
Source 3: Original clinical research
ebi.ac.uk · Source check Sep 10, 2026
Population: 54 adults randomized in a 12-week exploratory prediabetes trial; glucose-lowering and anti-obesity medicines were excluded.
Fasting and postprandial glucose improved relative to placebo, without a significant HbA1c change. The full body reports one light-headedness withdrawal described as possible hypoglycemia.
How this applies: Retains both glucose activity and the uncertain symptom report without inventing a combination risk estimate.
Possible event was not documented as glucose-confirmed hypoglycemia in the inspected narrative; no exact tirzepatide co-use. Small exploratory manufacturer-sponsored trial. Seed extract is not equivalent to food seasoning or every preparation.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Sources checked and article drafted. | |
| Research summary published |
Article revision: fd04c2ab52bff2c0
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.